TY - JOUR
T1 - An Unexplored Pharmacologic/Diagnostic Strategy for Peri-Implantitis
T2 - A Protocol Proposal
AU - Golub, Lorne M.
AU - Räisänen, Ismo T.
AU - Sorsa, Timo
AU - Preshaw, Philip M.
N1 - Funding Information:
Funding: This research was funded by the following institutions. For Lorne M. Golub, studies referred to in this review were supported in part by NIDCR/NIH grants R37-DE03987, R01DE012872, K16DE00275, K11DE00363, R41DE024946, R42DE024964, and by Johnson & Johnson; CollaGenex Pharmaceuticals, Inc.; Galderma R&D; Kroc Foundation Med. Res.; Traverse Biosciences Inc.; New York State Diabetes Association, and by Stony Brook Research account #1050308-37298. For Timo Sorsa, his studies were supported by grants from the University of Helsinki Research Foundation TYH2016251, TYH2017251, TYH2018229, TYH2019314, Y101SL017, Y1014SL018, Y1014SULE1, Helsinki, Finland and the Karolinska Institute, Stockholm, Sweden. For Philip M. Preshaw, he has received research funding, honoraria and travel grants from Philips Research and from Colgate.
Funding Information:
This research was funded by the following institutions. For Lorne M. Golub, studies referred to in this review were supported in part by NIDCR/NIH grants R37-DE03987, R01DE012872, K16DE00275, K11DE00363, R41DE024946, R42DE024964, and by Johnson & Johnson; CollaGenex Pharmaceuticals, Inc.; Galderma R&D; Kroc Foundation Med. Res.; Traverse Biosciences Inc.; New York State Diabetes Association, and by Stony Brook Research account #1050308-37298. For Timo Sorsa, his studies were supported by grants from the University of Helsinki Research Foundation TYH2016251, TYH2017251, TYH2018229, TYH2019314, Y101SL017, Y1014SL018, Y1014SULE1, Helsinki, Finland and the Karolinska Institute, Stockholm, Sweden. For Philip M. Preshaw, he has received research funding, honoraria and travel grants from Philips Research and from Colgate. Conflicts of Interest: Lorne M. Golub is listed as an inventor on several patents on host-modulation therapies and.
Publisher Copyright:
© 2020 by the authors. Licensee MDPI, Basel, Switzerland.
PY - 2020/12/5
Y1 - 2020/12/5
N2 - Dental implants are widely utilized for the replacement of missing teeth and are increasingly being placed in patients with systemic diseases, as well as in those who are medically healthy. Furthermore, it is recognized that peri-implant mucositis and peri-implantitis are highly prevalent, affecting large numbers of patients with implants, and it is pertinent to consider whether there may be any systemic impact of these conditions, given that there are known links between periodontitis and a number of chronic inflammatory diseases. In this article, we propose that the potential systemic complications of peri-implant diseases should be investigated in future clinical research, together with studies to identify whether systemically-administered host modulation therapies (HMTs) may be of benefit in the treatment of peri-implant diseases. These “HMTs” may prove a useful adjunct to routinely employed debridement and disinfection protocols, as well as potentially being of benefit in reducing risks of systemic complications. We also consider the use of chair-side diagnostic tests for active matrix metalloproteinase-8 (aMMP-8) in the detection of peri-implant disease given the ability of such tests to detect active tissue breakdown associated with peri-implantitis and periodontitis before conventional clinical and radiographic measurements indicate pathologic changes. These novel diagnostic and therapeutic strategies are relevant to consider as they may improve the management of peri-implant disease (beyond local debridement procedures), especially in those patients in whom systemic inflammation might be of concern.
AB - Dental implants are widely utilized for the replacement of missing teeth and are increasingly being placed in patients with systemic diseases, as well as in those who are medically healthy. Furthermore, it is recognized that peri-implant mucositis and peri-implantitis are highly prevalent, affecting large numbers of patients with implants, and it is pertinent to consider whether there may be any systemic impact of these conditions, given that there are known links between periodontitis and a number of chronic inflammatory diseases. In this article, we propose that the potential systemic complications of peri-implant diseases should be investigated in future clinical research, together with studies to identify whether systemically-administered host modulation therapies (HMTs) may be of benefit in the treatment of peri-implant diseases. These “HMTs” may prove a useful adjunct to routinely employed debridement and disinfection protocols, as well as potentially being of benefit in reducing risks of systemic complications. We also consider the use of chair-side diagnostic tests for active matrix metalloproteinase-8 (aMMP-8) in the detection of peri-implant disease given the ability of such tests to detect active tissue breakdown associated with peri-implantitis and periodontitis before conventional clinical and radiographic measurements indicate pathologic changes. These novel diagnostic and therapeutic strategies are relevant to consider as they may improve the management of peri-implant disease (beyond local debridement procedures), especially in those patients in whom systemic inflammation might be of concern.
KW - AMMP-8
KW - Dental implants
KW - Host modulation therapies
KW - Matrix metalloproteinase 8
KW - Matrix metalloproteinases
KW - Peri-implant mucositis
KW - Peri-implantitis
KW - Periodontitis
UR - http://www.scopus.com/inward/record.url?scp=85105858310&partnerID=8YFLogxK
U2 - 10.3390/diagnostics10121050
DO - 10.3390/diagnostics10121050
M3 - Article
AN - SCOPUS:85105858310
SN - 2075-4418
VL - 10
JO - Diagnostics
JF - Diagnostics
IS - 12
M1 - 1050
ER -